Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Menendez picked for N.J. Senate seat

Executive Summary

N.J. Gov.-elect John Corzine (D) names House Democratic Caucus Chair Robert Menendez (D) to his recently vacated Senate seat Dec. 9. A special election could be held for Menendez's vacated 13th district seat, which borders Merck's Rahway research facility. House Energy & Commerce Committee member Frank Pallone (D-N.J.), whose sixth district includes Johnson & Johnson's New Brunswick headquarters, had pursued the appointment, as had most of the state's Democratic congressional delegation (1"The Pink Sheet" Nov. 14, 2005, p. 22). Pallone will now weigh his options of whether to run for the Senate seat in 2006...

You may also be interested in...

Candidates For Corzine’s Senate Seat Include Reps. From Pharma Districts

Candidates to replace the open Senate seat to be vacated by Governor-elect Jon Corzine (D-N.J.) include congressmen with significant pharmaceutical manufacturer constituencies

Harmonization Of The EU Regulatory Compliance Role: Many PRRC Issues To Be Clarified

Efforts are underway to create a harmonized approach among Persons Responsible for Regulatory Compliance who play a pivotal role in meeting the requirements of the EU MDR and IVDR. And liability issues are high on the agenda.

India To Scrap Intellectual Property Appellate Board

Legal experts explain why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts